Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

pros and cons of new anticoagulation therapies, anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies | July 26, 2016 | Heidi Olson, Pharm.D
With the recent introduction of several novel oral anticoagulants (NOACs) on the U.S. market that have been billed by...
atrial fibrillation, stroke risk, aspirin vs blood thinners, JACC study
News | Antiplatelet and Anticoagulation Therapies | June 24, 2016
June 24, 2016 — More than 1 in 3 atrial fibrillation (AF) patients at intermediate to high risk for stroke are treated...
female patients, atrial fibrillation, blood thinning therapy, AFDST, decision support tool, Cincinnati
News | Antiplatelet and Anticoagulation Therapies | June 02, 2016
June 2, 2016 — Female atrial fibrillation patients are less likely than their male counterparts to receive blood...
anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies | May 25, 2016
May 25, 2016 — Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders | May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk...
News | Atrial Fibrillation | May 19, 2016
May 19, 2016 — Physician-researchers in the College of Medicine at the University of Cincinnati have developed a...
clot, coronary thrombus, antiplatelet therapt, DAPT

An intravascular ultrasound (IVUS) image of a thrombus formed in a coronary artery.  While there are guidelines for antiplatelet therapy, there are still questions over the duration of such therapy. 

Feature | Antiplatelet and Anticoagulation Therapies | May 19, 2016 | Marianne Pop, Pharm.D., BCPS
There were many opinions on the duration of dual antiplatelet therapy (DAPT) highlighted at the 2016 American College...
PROMETHEUS, anticoagulation in women
News | Antiplatelet and Anticoagulation Therapies | May 16, 2016
May 16, 2016 – Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute...
News | Antiplatelet and Anticoagulation Therapies | May 16, 2016
May 16, 2016 — A study on the impact of using different anticoagulation medications on men and women who have undergone...
daily oral anticoagulation therapy, OAT, atrial fibrillation, as needed, HRS 2016 study
News | Antiplatelet and Anticoagulation Therapies | May 09, 2016
May 9, 2016 — A new study shows the use of novel anticoagulants to treat atrial fibrillation (AF) on an “as needed...
warfarin, atrial fibrillation, dementia, Intermountain Healthcare Study, HRS 2016
News | Antiplatelet and Anticoagulation Therapies | May 09, 2016
May 9, 2016 — A new study has found an increased risk of dementia in patients with atrial fibrillation (AF) that...
warfarin, atrial fibrillation, kidney failure, HRS 2016
News | Antiplatelet and Anticoagulation Therapies | May 06, 2016
May 6, 2016 — Atrial fibrillation patients taking warfarin are at higher risk of developing kidney failure if...
SCAI 2016, PCI, bleeding risk, bivalirudin, NCDR risk calculator, clinical trial
News | Antiplatelet and Anticoagulation Therapies | May 06, 2016
May 6, 2016 — The largest risk-directed study by a national hospital system demonstrates a 40 percent decline in...
Xarelto, rivaroxaban, PMSS study, ACC 2016, NVAF, atrial fibrillation, stroke
News | Antiplatelet and Anticoagulation Therapies | April 08, 2016
April 8, 2016 — New data from an ongoing post-marketing study confirm the safety profile of Xarelto (rivaroxaban) was...
Brilinta, ticagrelor, ACC-AHA guideline, acute coronary syndrome
News | Antiplatelet and Anticoagulation Therapies | April 01, 2016
April 1, 2016 — AstraZeneca confirmed that the American College of Cardiology (ACC) and American Heart Association (AHA...